CSIMarket Company Name, Ticker, Suppliers, else..
 
Supernus Pharmaceuticals inc   (NASDAQ: SUPN)
 
Price: $42.0700 $-0.36 -0.848%
Day's High: $42.59000015258789 Week Perf: -4.45 %
Day's Low: $ 41.50 30 Day Perf: -10.62 %
Volume (M): 580,125 52 Wk High: $ 59.68
Volume (M$): $ 0 52 Wk Avg: $48.48
Open: $42.17 52 Wk Low: $41.50



 Market Capitalization (Millions $) 2,425
 Shares Outstanding (Millions) 58
 Employees 652
 Revenues (TTM) (Millions $) 777
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) 70
 Capital Exp. (TTM) (Millions $) 1

Business Description


Supernus Pharmaceuticals is a pharmaceutical company that specializes in the development and commercialization of treatments for central nervous system (CNS) disorders. The company was founded in 2005 and is headquartered in Rockville, Maryland, USA.

Supernus has a diverse portfolio of products in various stages of development. The company's leading products include Oxtellar XR, a treatment for partial onset seizures in adults and children, and Trokendi XR, a treatment for migraines and epilepsy. Additionally, Supernus is developing other treatments for CNS disorders, including ADHD, schizophrenia, and depression.

The company's management team has extensive experience in the pharmaceutical industry and has a track record of successful drug development and commercialization. The company has a robust intellectual property portfolio, including patents for its lead products.

Supernus has a strong partnership with the FDA and has received several FDA approvals for its products. The company also focuses on the development of drugs with improved delivery methods, including sustained-release formulations and transdermal patches.

In addition to its drug development pipeline, Supernus has a strong financial position with significant cash reserves and revenue growth. The company also has partnerships with several other pharmaceutical companies to develop and commercialize their products.

Overall, Supernus Pharmaceuticals is a well-established pharmaceutical company with a strong focus on innovation and drug development for CNS disorders. The company's diverse portfolio of products, strong management team, and financial position make it a promising player in the pharmaceutical industry.


   Company Address: 9715 Key West Avenue Rockville 20850 MD
   Company Phone Number: 838-2500   Stock Exchange / Ticker: NASDAQ SUPN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.49%    
BMY   -3.75%    
REGN   -1.96%    
TEVA        1.82% 
VRTX   -4.84%    
VTRS   -0.78%    
• View Complete Report
   



Partnership

Navigating the ADHD Journey Together Jay and Rosie Glazer’s Insightful Exploration on Love, Challenges, and Qelbree

Published Thu, May 29 2025 3:53 PM UTC

In the realm of mental health, awareness is an empowering tool. From celebrities to everyday individuals, the narratives around conditions like Attention Deficit Hyperactivity Disorder (ADHD) are being shared more openly, paving the way for understanding, acceptance, and support. One such enlightening endeavor is the new video content series launched by Jay Glazer and his wi...
Product Service News

Resubmission of SPN-830 NDA A Step Forward in Parkinsons Disease Management

Published Thu, Aug 1 2024 8:30 PM UTC

In a significant development within the field of neurology, Supernus Pharmaceuticals, Inc. has announced the resubmission of its New Drug Application (NDA) for SPN-830, an innovative apomorphine infusion device aimed at providing continuous treatment for motor fluctuations in patients with Parkinson s disease (PD). This announcement, made on August 1, 2024, highlights Supern...
Clinical Study

Supernus Pharmaceuticals Reports Promising Interim Results from Phase 2a Study of SPN-817, A Novel Acetylcholinesterase Inhibitor for Epilepsy Treatment

Published Thu, May 23 2024 8:06 PM UTC

Epilepsy, a neurological disorder characterized by recurrent, unprovoked seizures, affects millions of individuals worldwide. Despite numerous available treatments, a significant percentage of patients continue to suffer from uncontrolled seizures, highlighting the dire need for new therapeutic avenues. Supernus Pharmaceuticals, Inc., a company renowned for its innovative ap...
Product Service News

Supernus Pharmaceuticals' SPN-830 Infusion Device Advances in FDA Review: A Potential Breakthrough in Managing Parkinson's Disease 'Off Episodes'

Published Mon, Apr 8 2024 12:01 PM UTC

Supernus Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Rockville, Maryland, specializing in the development and commercialization of products for the treatment of central nervous system (CNS) diseases, announced new progress regarding the ongoing regulatory procedures of the SPN-830 infusion device. SPN-830, an investigational apomorphine infusion device, ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.12
Price to Sales (Expected) -
Price to Book 2.25
PEG (TTM) -

Financial Strength Current
Quick Ratio 1
Working Capital Ratio 3.97
Leverage Ratio (MRQ) 0.39
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.51 $
Revenues (TTM) 13.48 $
Cash Flow (TTM) 1.22 $
Cash 3.21 $
Book Value 18.68 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,191,462
Net Income per Employee (TTM) -44,503
Receivable Turnover Ratio (TTM) 4.56
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.54

Profitability Ratios Current
Gross Margin (MRQ) 88.74 %
Operating Margin (MRQ) -4.01 %
Net Margin (MRQ) -1.1 %
Net Cash Flow Margin (MRQ) 27.16 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Supernus Pharmaceuticals Inc's Segments
Net product sales    72.58 % of total Revenue
Qelbree    37.48 % of total Revenue
GOCOVRI    16.97 % of total Revenue
Trokendi XR    4.56 % of total Revenue
ONAPGO    4.03 % of total Revenue
APOKYN    3.72 % of total Revenue
Oxtellar XR    3.57 % of total Revenue
Other    2.25 % of total Revenue
Collaboration revenue ZURZUVAE    13.31 % of total Revenue
Royalty licensing and other revenues    14.11 % of total Revenue
Shionogi License    9.63 % of total Revenue
Reportable Segment    100 % of total Revenue
Biogen Collaboration Agreement    13.31 % of total Revenue

  Supernus Pharmaceuticals Inc Outlook

On October 25 2023 the Supernus Pharmaceuticals Inc provided following guidance

Supernus Pharmaceuticals, a leading biopharmaceutical company specializing in the development and commercialization of CNS disease tr...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.